Ensysce’s TAAP™ prodrug technology is a game changer in the abuse deterrent field


Ensysce Biosciences' proprietary abuse-resistant prodrug technology – the TAAP™ platform - is designed to improve the care of patients while reducing the human and economic costs associated with prescription drug abuse. Our TAAP™ technology has been applied to a family of opioid and attention deficit disorder products.

  • Several abuse-deterrent opioid products are currently marketed or in late-stage clinical development, but they fall short of being fully resistant to abuse.

  • Our prodrugs are chemically stable molecules that are activated only when administered orally

  • Since the activating enzymes are not present in the blood or saliva, there is no opportunity for activation if injected, chewed or snorted

In addition, Ensysce's Multi-Pill Abuse Resistant - MPAR™ - technology is designed to provide another layer of protection to our TAAP™ products. It is unique to the industry and designed not only to overcome abuse but to save lives by preventing overdose.